Simcere Enters Co-development Partnership With San Francisco Biotech Outfit On Monoclonal Antibody Treatment, Scans China For Takeover Targets
This article was originally published in PharmAsia News
Executive Summary
BEIJING - While reporting a strong rise in earnings for 2008, the leaders of China's Simcere Pharmaceutical Group said they have signed a co-development deal with a San Francisco biotech firm on a monoclonal antibody treatment for cancer
You may also be interested in...
Chinese Pharma Simcere Files IND For Humanized Rabbit Monoclonal Antibody
HONG KONG - Chinese drug manufacturer and distributor Simcere Pharmaceutical Group filed an investigational new drug application earlier this month with China's State FDA to launch a Phase I trial of APX003, a novel humanized rabbit monoclonal antibody to treat solid-tumor cancer
Chinese Pharma Simcere Files IND For Humanized Rabbit Monoclonal Antibody
HONG KONG - Chinese drug manufacturer and distributor Simcere Pharmaceutical Group filed an investigational new drug application earlier this month with China's State FDA to launch a Phase I trial of APX003, a novel humanized rabbit monoclonal antibody to treat solid-tumor cancer
Simcere Will Co-Develop Cancer Drugs With BMS; A New R&D Model Between China And U.S.?
SHANGHAI - While reporting strong growth in the third quarter, New York-listed Chinese pharma Simcere focused attention on its recent deal with Bristol-Myers Squibb to co-develop BMS-817378, a small molecule MET/VEGFR-2 inhibitor now in preclinical development